Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology

@article{Labrie2015CombinedBO,
  title={Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology},
  author={Fernand Labrie},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2015},
  volume={145},
  pages={144-156}
}
  • F. Labrie
  • Published 31 January 2015
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
Recently two drugs, namely the antiandrogen MDV-3100 and the inhibitor of 17α-hydroxylase abiraterone have been accepted by the FDA for the treatment of castration-resistant prostate cancer (CRPC) with or without previous chemotherapy, with a prolongation of overall survival of 2.2-4.8 months. While medical (GnRH agonist) or surgical castration reduces the serum levels of testosterone by about 97%, an important concentration of testosterone and dihydrotestosterone remains in the prostate and… Expand

Paper Mentions

Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer
TLDR
The therapeutic implications include the inhibition of AKR1C3 in tumors that become resistant to current drugs such as abiraterone acetate or Enza and the potential administration of D4A as an mCRPC therapeutic. Expand
The importance of targeting intracrinology in prostate cancer management
TLDR
Several drugs have been developed that target intracrinology, some of which are now being used as standard treatment for the so-called castrate-resistant prostate cancer patients, but question is whether those drugs can also be used as the first-line treatment in localized stage PCa cases. Expand
Targeting extra-gonadal androgens in castration-resistant prostate cancer
TLDR
Understanding this persistent dependency and adaptation to the androgen axis in CRPC will lead to an understanding of resistance to new licensed therapies and to novel drug discovery, ultimately improving clinical outcome inCRPC. Expand
Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
TLDR
Although L HRH agonists are still the mainstay for treatment of advanced PCa, antagonists of LHRH offer an alternative as a pharmacological approach. Expand
Role of Hormonal Manipulation in Prostate Cancer Management
TLDR
The present review summarises the chronological evolution of agents used for hormonal manipulation in the management of PCa, highlighting the pros and cons of each and sheds light on the potential future advances in this area. Expand
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature
  • I. Bird, D. Abbott
  • Biology, Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2016
TLDR
It is concluded that a future for improved therapy without substantial cortisol decline, thus avoiding prednisone co-administration, seems possible at long last. Expand
Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database
TLDR
Although there is no FDA indication for BIC use as monotherapy, 44% of patients in this study used BIC alone or as part of CAB followed by monotherapy; further research is necessary to understand the outcomes of BIC utilization in these settings, particularly compared with newer second-generation anti-androgens. Expand
New insights into the androgen biotransformation in prostate cancer: A regulatory network among androgen, androgen receptors and UGTs.
TLDR
The regulatory network among androgen, androgen receptors (AR) and UGTs is carefully reviewed, indicating the determinant effects of U GTs on prostatic androgens and the regulation of AR. Expand
Roles of renin-angiotensin system in the regulation of prostate cancer bone metastasis: a critical review
  • annals of urologic oncology
  • 2021
Mestastatic prostate cancer cells (MPCCs) frequently metastasize to bone, which is a “favorite soil” for colonization and proliferation of MPCCs. Prostate cancer bone mestastasis is tightlyExpand
Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer
TLDR
Evidence is shown that the androgen receptor contributes to the reprogramming of specific cellular metabolic pathways that promote tumor growth and disease progression, including aerobic glycolysis, mitochondrial respiration, fatty acid ß-oxidation, and de novo lipid synthesis. Expand
...
1
2
...

References

SHOWING 1-10 OF 149 REFERENCES
Blockade of testicular and adrenal androgens in prostate cancer treatment
TLDR
Combined androgen blockade—medical or surgical castration plus a pure antiandrogen—would be the logical first-line treatment for prostate cancer, although castration or an antiandrogens alone is still chosen in the majority of cases. Expand
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
  • G. Attard, A. Reid, +16 authors J. D. de Bono
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
YP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven. Expand
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
TLDR
In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%. Expand
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
TLDR
It is indicated that a combined hormonal therapy which neutralizes all androgenic influences on peripheral tissues is of potential benefit in prostatic cancer and should minimize the development of metastases and androgen-resistant cell clones. Expand
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.
TLDR
It is indicated that prostate cancers undergo an adaptive response to castration that is associated with the up-regulation of transcripts encoding enzymes involved in the biosynthesis of androgens, and targeting these metabolic enzymes either individually or using combinations of agents to inhibit testicular, adrenal, and intracrine sources may provide enhanced clinical responses. Expand
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
TLDR
The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer. Expand
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
  • G. Attard, A. Reid, +13 authors J. D. de Bono
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC, and data confirm that CRPC commonly remains dependent on ligand-activated AR signaling. Expand
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
  • H. Scher, C. Sawyers
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Strategies that are focused on the androgen receptor either directly or indirectly, as single agents or in combination, that are in clinical development that are discussed are discussed. Expand
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
TLDR
It is demonstrated that DHEA and A5diol must be metabolized by 3betaHSD to activate AR in these models of CRPC, and suggests that 3 betaHSD may be exploited as a pharmacologic target in the treatment ofCRPC. Expand
...
1
2
3
4
5
...